Trial · NCT00869401
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | 15.6 | 95% Confidence Interval 14.4 to 19.6 | Months | |
| Overall Survival | Group 2 (Phase II) Placebo + Radiation + Temozolomide | 19.3 | 95% Confidence Interval 16.1 to 21.7 | Months | |
| The Number of Dose Limiting Toxicities(DLT) in Order to Determine Maximum Tolerable Dose(MTD) of Dasatinib Combined With Radiation and Temozolomide in This Patient Population. | Dose Level 0 Phase I | 1 | participants with Dose Limiting Toxicits | ||
| The Number of Dose Limiting Toxicities(DLT) in Order to Determine Maximum Tolerable Dose(MTD) of Dasatinib Combined With Radiation and Temozolomide in This Patient Population. | Dose Level 0-A Phase I | 0 | participants with Dose Limiting Toxicits | ||
| The Number of Dose Limiting Toxicities(DLT) in Order to Determine Maximum Tolerable Dose(MTD) of Dasatinib Combined With Radiation and Temozolomide in This Patient Population. | Dose Level 1 Phase I | 1 | participants with Dose Limiting Toxicits | ||
| Progression-free Survival | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | 6.2 | 95% Confidence Interval 4.4 to 8.2 | Months | |
| Progression-free Survival | Group 2 (Phase II) Placebo + Radiation + Temozolomide | 7.8 | 95% Confidence Interval 6.5 to 10.9 | Months | |
| Objective Response | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | Progression | .31 | Proportion of participants | |
| Objective Response | Group 2 (Phase II) Placebo + Radiation + Temozolomide | Progression | .19 | Proportion of participants | |
| Objective Response | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | Stable | .59 | Proportion of participants | |
| Objective Response | Group 2 (Phase II) Placebo + Radiation + Temozolomide | Stable | .73 | Proportion of participants | |
| Objective Response | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | REGR | .08 | Proportion of participants | |
| Objective Response | Group 2 (Phase II) Placebo + Radiation + Temozolomide | REGR | .02 | Proportion of participants | |
| Objective Response | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | Partial Response | .02 | Proportion of participants | |
| Objective Response | Group 2 (Phase II) Placebo + Radiation + Temozolomide | Partial Response | .06 | Proportion of participants | |
| Objective Response | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | Complete Response | 0 | Proportion of participants | |
| Objective Response | Group 2 (Phase II) Placebo + Radiation + Temozolomide | Complete Response | 0 | Proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00869401/results